Literature DB >> 24523215

Deaths among people with hepatitis C in New York City, 2000-2011.

Jessie Pinchoff1, Ann Drobnik, Katherine Bornschlegel, Sarah Braunstein, Christine Chan, Jay K Varma, Jennifer Fuld.   

Abstract

BACKGROUND: Infection with hepatitis C virus (HCV) increases the risk of death from liver and nonliver-related diseases. Coinfection with human immunodeficiency virus (HIV) further increases this risk.
METHODS: Surveillance data (2000-2010) and mortality data (2000-2011) maintained by the New York City Department of Health and Mental Hygiene (DOHMH) were deterministically cross-matched. Factors associated with and causes of death among HCV-infected adult decedents were analyzed.
RESULTS: Between 2000 and 2011, 13 307 HCV-monoinfected adults died, and 5475 adults coinfected with HCV/HIV died. Decedents with HCV monoinfection were more likely to have died of liver cancer (odds ratio [OR] = 9.2), drug-related causes (OR = 4.3), and cirrhosis (OR = 3.7), compared with persons with neither infection. HCV/HIV-coinfected decedents were more likely to have died of liver cancer (OR = 2.2) and drug-related causes (OR = 3.1), compared with persons with neither infection. Among coinfected decedents, 53.6% of deaths were attributed to HIV/AIDS, and 94% of deaths occurred prematurely (before age 65). Among persons with HCV who died, more than half died within 3 years of an HCV report to DOHMH.
CONCLUSIONS: HCV-infected adults were at increased risk of dying and of dying prematurely, particularly from conditions associated with HCV, such as HIV/AIDS or drug use. The short interval between HCV report and death suggests a need for earlier testing and improved treatment.

Entities:  

Keywords:  HIV; coinfection; hepatitis C; mortality; surveillance

Mesh:

Year:  2014        PMID: 24523215     DOI: 10.1093/cid/ciu075

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  Neighborhood Inequalities in Hepatitis C Mortality: Spatial and Temporal Patterns and Associated Factors.

Authors:  Mary M Ford; Payal S Desai; Gil Maduro; Fabienne Laraque
Journal:  J Urban Health       Date:  2017-10       Impact factor: 3.671

2.  Hepatitis C virus testing for case identification in persons born during 1945-1965: Results from three randomized controlled trials.

Authors:  Anthony K Yartel; David B Rein; Kimberly Ann Brown; Katherine Krauskopf; Omar I Massoud; Cynthia Jordan; Natalie Kil; Alex D Federman; David R Nerenz; Joanne E Brady; Danielle L Kruger; Bryce D Smith
Journal:  Hepatology       Date:  2018-01-02       Impact factor: 17.425

3.  Modelling the prevalence of hepatitis C virus amongst blood donors in Libya: An investigation of providing a preventive strategy.

Authors:  Mohamed A Daw; Amira Shabash; Abdallah El-Bouzedi; Aghnya A Dau; Moktar Habas
Journal:  World J Virol       Date:  2016-02-12

4.  Statin drugs decrease progression to cirrhosis in HIV/hepatitis C virus coinfected individuals.

Authors:  Nora T Oliver; Christine M Hartman; Jennifer R Kramer; Elizabeth Y Chiao
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

5.  Hepatitis C Virus Disease Progression in People Who Inject Drugs: Protocol for a Systematic Review and Meta-Analysis.

Authors:  Joan Combellick; Daniel J Smith; Ashly E Jordan; Holly Hagan
Journal:  JMIR Res Protoc       Date:  2015-06-08

6.  Mortality trend due to Hepatitis B and C in the city of São Paulo, 2002-2016.

Authors:  Ana Paula Sayuri Sato; Inês Kazue Koizumi; Norma Suely de Oliveira Farias; Célia Regina Ciccolo da Silva; Maria Regina Alves Cardoso; Gerusa Maria Figueiredo
Journal:  Rev Saude Publica       Date:  2020-12-04       Impact factor: 2.106

7.  Impact of hepatitis B on mortality and specific causes of death in adults with and without HIV co-infection in NYC, 2000-2011.

Authors:  J Pinchoff; O C Tran; L Chen; K Bornschlegel; A Drobnik; L Kersanske; J Fuld
Journal:  Epidemiol Infect       Date:  2016-08-11       Impact factor: 4.434

Review 8.  APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.

Authors:  Masao Omata; Tatsuo Kanda; Lai Wei; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Mamun Al-Mahtab; Geofferey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Osamu Yokosuka; George K K Lau; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-05-26       Impact factor: 6.047

9.  Hepatitis C coinfection adversely affects the life expectancy of people living with HIV in northwestern Poland.

Authors:  Magdalena Leszczyszyn-Pynka; Piotr Ciejak; Katarzyna Maciejewska; Magdalena Witak-Jędra; Malwina Karasińska-Cieślak; Ewa Karpińska; Marta Wawrzynowicz-Syczewska; Miłosz Parczewski
Journal:  Arch Med Sci       Date:  2016-03-23       Impact factor: 3.318

10.  Effect of Hepatocellular Carcinoma on Mortality Among Individuals With Hepatitis B or Hepatitis C Infection in New York City, 2001-2012.

Authors:  Miranda S Moore; Angelica Bocour; Olivia C Tran; Baozhen Qiao; Maria J Schymura; Fabienne Laraque; Ann Winters
Journal:  Open Forum Infect Dis       Date:  2018-06-16       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.